Terumi Tanigawa

9PUBLICATIONS
49CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 07, 2026
Real-world safety and effectiveness of olaparib maintenance after first-relapse platinum-sensitive ovarian cancer in Japan: a multicenter historical cohort (JGOG3026).

|Mar 30, 2026
Effect of first-line poly(ADP-ribose) polymerase inhibitor on second-line platinum-based chemotherapy in epithelial ovarian cancer.

Yusuke Toyohara, Mayu Yunokawa, Ryo Nimura

|Mar 28, 2025
The impact of cytoreductive surgery on outcomes in high tumor burden ovarian cancer after induction of PARP inhibitors.

Motoko Kanno, Mayu Yunokawa, Atsushi Fusegi

|Dec 06, 2024
The efficacy and safety of lenvatinib plus pembrolizumab in vulnerable patients with metastatic or recurrent endometrial cancer: a single institution experience.

Mayu Yunokawa, Akiko Abe, Xiaofei Wang

|Jul 21, 2023
Efficacy of intra-abdominal cytoreductive surgery in advanced endometrial cancer with distant metastasis.

Motoko Kanno, Mayu Yunokawa, Nozomi Kurihara

|Apr 28, 2023
An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group.

Muneaki Shimada, Kosuke Yoshihara, Terumi Tanigawa

Pageof 2

Frequent Collaborators

7 joint publications

Hiroyuki Kanao

5 joint publications

Yoichi Aoki

5 joint publications

Mayu Yunokawa

4 joint publications

Motoko Kanno